

PROTAC targeted protein degraders: the past is prologue

Nature Reviews Drug Discovery

21, 181-200

DOI: [10.1038/s41573-021-00371-6](https://doi.org/10.1038/s41573-021-00371-6)

Citation Report

#	ARTICLE	IF	CITATIONS
3	Discovery of Thieno[2,3- <i>c</i>]indazole Derivatives as Novel Oral Selective Estrogen Receptor Degraders with Highly Improved Antitumor Effect and Favorable Druggability. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 5724-5750.	2.9	8
4	Targeted protein degraders: a call for collective action to advance safety assessment. <i>Nature Reviews Drug Discovery</i> , 2022, , .	21.5	9
5	Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias. <i>Journal of Hematology and Oncology</i> , 2022, 15, 35.	6.9	18
6	Clinical considerations for the design of PROTACs in cancer. <i>Molecular Cancer</i> , 2022, 21, 67.	7.9	37
7	Development of an LC-MS/MS Method for ARV-110, a PROTAC Molecule, and Applications to Pharmacokinetic Studies. <i>Molecules</i> , 2022, 27, 1977.	1.7	26
10	FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021. <i>Molecules</i> , 2022, 27, 2259.	1.7	14
11	Co-aggregation and secondary nucleation in the life cycle of human prolactin/galanin functional amyloids. <i>ELife</i> , 2022, 11, .	2.8	9
12	Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective. <i>Frontiers in Oncology</i> , 2022, 12, 865350.	1.3	12
13	Targeted protein degradation: mechanisms, strategies and application. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 113.	7.1	162
14	Targeting epigenetic modulators using PROTAC degraders: Current status and future perspective. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 63, 128653.	1.0	18
15	The state of the art of PROTAC technologies for drug discovery. <i>European Journal of Medicinal Chemistry</i> , 2022, 235, 114290.	2.6	45
16	Translational PK&PD for targeted protein degradation. <i>Chemical Society Reviews</i> , 2022, 51, 3477-3486.	18.7	17
18	Smart PROTACs Enable Controllable Protein Degradation for Precision Cancer Therapy. <i>Molecular Diagnosis and Therapy</i> , 2022, 26, 283-291.	1.6	3
19	DUB to the rescue. <i>Molecular Cell</i> , 2022, 82, 1411-1413.	4.5	1
20	Designing Soluble PROTACs: Strategies and Preliminary Guidelines. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 12639-12649.	2.9	33
21	Evolution of 3-(4-hydroxyphenyl)indoline-2-one as a scaffold for potent and selective anticancer activity. <i>RSC Medicinal Chemistry</i> , 2022, 13, 711-725.	1.7	1
22	Degrader-antibody conjugates. <i>Chemical Society Reviews</i> , 2022, 51, 3886-3897.	18.7	41
23	Overcoming Cancer Drug Resistance Utilizing PROTAC Technology. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 872729.	1.8	32

#	ARTICLE	IF	CITATIONS
24	Roadmap for Optimizing and Broadening Antibody-Based PROTACs for Degradation of Cell Surface Proteins. <i>ACS Chemical Biology</i> , 2022, 17, 1259-1268.	1.6	32
25	Application of Rapidly Accelerating Fibrosarcoma Protein Degraders in Drug Discovery. <i>ACS Medicinal Chemistry Letters</i> , 0, , .	1.3	0
26	Ubiquitin and Ubiquitin-like Proteins in Cancer, Neurodegenerative Disorders, and Heart Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5053.	1.8	22
27	Helical Foldamers and Stapled Peptides as New Modalities in Drug Discovery: Modulators of Protein-Protein Interactions. <i>Processes</i> , 2022, 10, 924.	1.3	8
28	Identification of novel and potent PROTACs targeting FAK for non-small cell lung cancer: Design, synthesis, and biological study. <i>European Journal of Medicinal Chemistry</i> , 2022, 237, 114373.	2.6	10
29	More to the RAS Story: KRAS ^{G12C} Inhibition, Resistance Mechanisms, and Moving Beyond KRAS ^{G12C} . <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 205-217.	1.8	13
30	E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188736.	3.3	36
32	Novel, highly potent PROTACs targeting AURORA-A kinase. <i>Current Research in Chemical Biology</i> , 2022, 2, 100032.	1.4	9
34	PROTAC mediated FKBP12 degradation enhances Hecpudin expression via BMP signaling without immunosuppression activity. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	4
35	PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective. , 2022, 1, .		13
36	HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer. <i>Pharmaceuticals</i> , 2022, 15, 667.	1.7	15
38	Molecular Glues: Capable Protein-Binding Small Molecules That Can Change Protein-Protein Interactions and Interactomes for the Potential Treatment of Human Cancer and Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6206.	1.8	9
39	Selectivity through Targeted Protein Degradation (TPD). <i>Journal of Medicinal Chemistry</i> , 2022, 65, 8113-8126.	2.9	15
40	Degrading boundaries to break new ground in chemical biology. <i>Current Research in Chemical Biology</i> , 2022, 2, 100033.	1.4	1
41	PROTACs: past, present and future. <i>Chemical Society Reviews</i> , 2022, 51, 5214-5236.	18.7	180
42	Chasing molecular glue degraders: screening approaches. <i>Chemical Society Reviews</i> , 2022, 51, 5498-5517.	18.7	55
43	Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation. <i>Chemical Society Reviews</i> , 2022, 51, 5330-5350.	18.7	50
45	PROTACs: great opportunities for academia and industry (an update from 2020 to 2021). <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	77

#	ARTICLE	IF	CITATIONS
46	On-Chip Preconcentration Microchip Capillary Electrophoresis Based CE-PRM-LIVE for High-Throughput Selectivity Profiling of Deubiquitinase Inhibitors. <i>Analytical Chemistry</i> , 2022, 94, 9508-9513.	3.2	2
47	SARS-CoV-2: Novel Therapeutic Approaches for Diagnosis and Treatment. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 999-1001.	1.3	0
48	Beyond Proteolysis-Targeting Chimeric Molecules: Designing Heterobifunctional Molecules Based on Functional Effectors. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 8091-8112.	2.9	25
49	Proteolysis Targeting Chimeric Molecules: Tuning Molecular Strategies for a Clinically Sound Listening. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6630.	1.8	8
50	Recent advances in the development of EGFR degraders: PROTACs and LYTACs. <i>European Journal of Medicinal Chemistry</i> , 2022, 239, 114533.	2.6	16
51	The importance of cellular degradation kinetics for understanding mechanisms in targeted protein degradation. <i>Chemical Society Reviews</i> , 2022, 51, 6210-6221.	18.7	12
52	Targeted Degradation of STAT3 via Chaperone-Mediated Autophagy by nanoCMATAC Platform. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
53	Targeting the deubiquitinase USP7 for degradation with PROTACs. <i>Chemical Communications</i> , 2022, 58, 8858-8861.	2.2	13
54	Protein-Protein Interaction Prediction for Targeted Protein Degradation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7033.	1.8	4
55	Digesting the Role of JAK-STAT and Cytokine Signaling in Oral and Gastric Cancers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
57	Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 8798-8827.	2.9	15
58	Current progress and novel strategies that target CDK12 for drug discovery. <i>European Journal of Medicinal Chemistry</i> , 2022, 240, 114603.	2.6	8
59	Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 9507-9530.	2.9	14
60	Applications and Limitations of Oxime-Linked "Split PROTACs". <i>ChemBioChem</i> , 2022, 23, .	1.3	6
61	ERK5 Signalling and Resistance to ERK1/2 Pathway Therapeutics: The Path Less Travelled?. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	9
62	Functional roles of E3 ubiquitin ligases in prostate cancer. <i>Journal of Molecular Medicine</i> , 2022, 100, 1125-1144.	1.7	6
63	Targeting the interaction of β -catenin and TCF/LEF transcription factors to inhibit oncogenic Wnt signaling. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 70, 116920.	1.4	11
64	Therapeutic and Effective CURE-PRO Molecules for E3 Ligase-Mediated Targeted Protein Degradation. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 1206-1208.	1.3	3

#	ARTICLE	IF	CITATIONS
65	Application of Selective SMARCA2/4 PROTAC for Mutant Cancer Therapy. ACS Medicinal Chemistry Letters, 2022, 13, 1209-1210.	1.3	0
66	Application of Degradation of Cyclic-AMP Response Element Binding Protein for the Potential Treatment of Cancer. ACS Medicinal Chemistry Letters, 2022, 13, 1211-1212.	1.3	0
67	Molecular Glues: The Adhesive Connecting Targeted Protein Degradation to the Clinic. Biochemistry, 2023, 62, 601-623.	1.2	43
68	Synthetic approaches to constructing proteolysis targeting chimeras (PROTACs). Mendeleev Communications, 2022, 32, 419-432.	0.6	0
69	Targeting cereblon in hematologic malignancies. Blood Reviews, 2023, 57, 100994.	2.8	8
70	Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade. Genes, 2022, 13, 1426.	1.0	4
71	Intracellular Delivery of Glutathione Peroxidase Degradable Induces Ferroptosis In Vivo. Angewandte Chemie, 0, , .	1.6	2
72	Key Considerations in Targeted Protein Degradation Drug Discovery and Development. Frontiers in Chemistry, 0, 10, .	1.8	7
73	Discovery of a Highly Potent and Selective Dual PROTAC Degradable of CDK12 and CDK13. Journal of Medicinal Chemistry, 2022, 65, 11066-11083.	2.9	18
74	Novel Design Strategies to Enhance the Efficiency of Proteolysis Targeting Chimeras. ACS Pharmacology and Translational Science, 2022, 5, 710-723.	2.5	11
76	Small-Molecule PROTACs for Cancer Immunotherapy. Molecules, 2022, 27, 5439.	1.7	8
77	Targeting UBE2C for degradation by bioPROTACs based on bacterial E3 ligase. Chinese Chemical Letters, 2023, 34, 107732.	4.8	4
78	Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood-Brain Barrier Penetrant PROTAC Degradable of Leucine-Rich Repeat Kinase 2. Journal of the American Chemical Society, 2022, 144, 16930-16952.	6.6	52
80	Intracellular Delivery of Glutathione Peroxidase Degradable Induces Ferroptosis In Vivo. Angewandte Chemie - International Edition, 2022, 61, .	7.2	39
82	Chemical and Enzymatic Methods for Post-Translational Protein-Protein Conjugation. Journal of the American Chemical Society, 2022, 144, 14404-14419.	6.6	30
83	BET inhibitors: an updated patent review (2018-2021). Expert Opinion on Therapeutic Patents, 2022, 32, 953-968.	2.4	7
84	UDP-Glucose: A Cereblon-Dependent Glucokinase Protein Degradable. International Journal of Molecular Sciences, 2022, 23, 9094.	1.8	4
85	Improving treatment for acute ischemic stroke-Clot busting innovation in the pipeline. Frontiers in Medical Technology, 0, 4, .	1.3	2

#	ARTICLE	IF	CITATIONS
86	Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins. Expert Opinion on Therapeutic Patents, 2022, 32, 1003-1026.	2.4	6
87	De Novo Design of an Androgen Receptor DNA Binding Domain-Targeted peptide PROTAC for Prostate Cancer Therapy. Advanced Science, 2022, 9, .	5.6	14
88	Targeting Akt/PKB in pediatric tumors: A review from preclinical to clinical trials. Pharmacological Research, 2022, 183, 106403.	3.1	10
89	Chemistries of bifunctional PROTAC degraders. Chemical Society Reviews, 2022, 51, 7066-7114.	18.7	73
90	Biologics-based degraders – an expanding toolkit for targeted-protein degradation. Current Opinion in Biotechnology, 2022, 78, 102807.	3.3	8
91	Design and optimization of oestrogen receptor PROTACs based on 4-hydroxytamoxifen. European Journal of Medicinal Chemistry, 2022, 243, 114770.	2.6	11
92	Methods to characterize and discover molecular degraders in cells. Chemical Society Reviews, 2022, 51, 7115-7137.	18.7	3
93	Discovery of Novel VEGFR-2-PROTAC Degraders Based on the Localization of Lysine Residues via Recruiting VHL for the Treatment of Gastric Cancer. SSRN Electronic Journal, 0, , .	0.4	0
94	A systematic analysis of biotech startups that went public in the first half of 2021. Current Research in Biotechnology, 2022, 4, 392-401.	1.9	5
95	SERDs: a case study in targeted protein degradation. Chemical Society Reviews, 2022, 51, 8149-8159.	18.7	4
96	The In-Cell Western immunofluorescence assay to monitor PROTAC mediated protein degradation. Methods in Enzymology, 2023, , 115-153.	0.4	1
97	Reactive oxygen species-responsive Pre-PROTAC for tumor-specific protein degradation. Chemical Communications, 2022, 58, 10072-10075.	2.2	15
98	High throughput E3 ligase degron binding assays for novel PROTAC ligand discovery. Methods in Enzymology, 2023, , 23-39.	0.4	3
99	A heterobifunctional molecule system for targeted protein acetylation in cells. Methods in Enzymology, 2022, , .	0.4	0
100	Targeted Protein Degradation to Overcome Resistance in Cancer Therapies: PROTAC and N-Degron Pathway. Biomedicines, 2022, 10, 2100.	1.4	5
101	Targeting tumor-associated MUC1 overcomes anoikis-resistance in pancreatic cancer. Translational Research, 2023, 253, 41-56.	2.2	23
102	MDM2-BCL-XL PROTACs enable degradation of BCL-XL and stabilization of p53. , 2022, 1, .		4
103	Discovery and Structural Characterization of Small Molecule Binders of the Human CTLH E3 Ligase Subunit GID4. Journal of Medicinal Chemistry, 2022, 65, 12725-12746.	2.9	20

#	ARTICLE	IF	CITATIONS
104	Linker-Dependent Folding Rationalizes PROTAC Cell Permeability. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 13029-13040.	2.9	30
105	A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10014.	1.8	12
106	Small-molecule Modulators Targeting SHP2 for Cancer Therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2023, 23, 498-504.	0.9	3
108	Recent Advances in Strategies for Imaging Detection and Intervention of Cellular Senescence. <i>ChemBioChem</i> , 2023, 24, .	1.3	8
109	Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy. <i>Cell Reports Physical Science</i> , 2022, 3, 101062.	2.8	12
110	Small Molecules for Enhancing the Precision and Safety of Genome Editing. <i>Molecules</i> , 2022, 27, 6266.	1.7	6
111	MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11068.	1.8	8
112	PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras. <i>BioDrugs</i> , 2022, 36, 609-623.	2.2	9
113	Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs). <i>Drug Discovery Today</i> , 2023, 28, 103387.	3.2	13
114	Development of Targeted EGFR Degradation for Cancer Treatment. , 2022, 122, 218-227.		0
115	Targeted Protein Degradation by Electrophilic PROTACs that Stereoselectively and Site-Specifically Engage DCAF1. <i>Journal of the American Chemical Society</i> , 2022, 144, 18688-18699.	6.6	44
116	New insights into genome folding by loop extrusion from inducible degron technologies. <i>Nature Reviews Genetics</i> , 2023, 24, 73-85.	7.7	29
117	Recent Advances of Degradation Technologies Based on PROTAC Mechanism. <i>Biomolecules</i> , 2022, 12, 1257.	1.8	15
118	Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 849-858.	2.5	18
119	Targeted Protein Degradation via Lysosomes. <i>Biochemistry</i> , 2023, 62, 564-579.	1.2	12
120	Hydrophobic Tag Tethering Degradation, The Emerging Targeted Protein Degradation Strategy. <i>Current Medicinal Chemistry</i> , 2023, 30, 3137-3155.	1.2	2
121	Fluorinated Cycloalkyl Building Blocks for Drug Discovery. <i>ChemMedChem</i> , 2022, 17, .	1.6	26
122	Small Molecule Tools to Study Cellular Target Engagement for the Intracellular Allosteric Binding Site of GPCRs. <i>Chemistry - A European Journal</i> , 2023, 29, .	1.7	4

#	ARTICLE	IF	CITATIONS
123	A "Cell Space Station" for Spatiotemporal Molecular Manipulation of Immune Checkpoint. ACS Nano, 2022, 16, 16332-16342.	7.3	1
124	Discovery of novel VEGFR-2-PROTAC degraders based on the localization of lysine residues via recruiting VHL for the treatment of gastric cancer. European Journal of Medicinal Chemistry, 2022, 244, 114821.	2.6	5
125	Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells. Journal of Medicinal Chemistry, 2022, 65, 14237-14260.	2.9	7
126	Natural Product-Inspired Targeted Protein Degraders: Advances and Perspectives. Journal of Medicinal Chemistry, 2022, 65, 13533-13560.	2.9	12
127	Recent Advances in PROTAC Technology Toward New Therapeutic Modalities. Chemistry and Biodiversity, 2022, 19, .	1.0	2
128	Analyzing the metabolic fate of oral administration drugs: A review and state-of-the-art roadmap. Frontiers in Pharmacology, 0, 13, .	1.6	0
129	Drug Hunting at the Nexus of Medicinal Chemistry and Chemical Biology and the Discovery of Novel Therapeutic Modalities. Journal of Medicinal Chemistry, 2022, 65, 13594-13613.	2.9	3
130	A comprehensive review of BET-targeting PROTACs for cancer therapy. Bioorganic and Medicinal Chemistry, 2022, 73, 117033.	1.4	9
131	The current status and future prospects for therapeutic targeting of KEAP1-NRF2 and β -TrCP-NRF2 interactions in cancer chemoresistance. Free Radical Biology and Medicine, 2022, 192, 246-260.	1.3	13
132	Discovery of potent and selective HER2 PROTAC degrader based Tucatinib with improved efficacy against HER2 positive cancers. European Journal of Medicinal Chemistry, 2022, 244, 114775.	2.6	7
133	Emerging degrader technologies engaging lysosomal pathways. Chemical Society Reviews, 2022, 51, 8832-8876.	18.7	35
134	The PROTAC selectively degrading Bcl-x _L represents a novel Hedgehog pathway inhibitor with capacity of combating resistance to Smoothed inhibitors while sparing bone growth. Theranostics, 2022, 12, 7476-7490.	4.6	5
135	It's ok to be outnumbered " sub-stoichiometric modulation of homomeric protein complexes. RSC Medicinal Chemistry, 2023, 14, 22-46.	1.7	2
136	Towards design of drugs and delivery systems with the Martini coarse-grained model. QRB Discovery, 2022, 3, .	0.6	8
137	Localization matters in targeted protein degradation. Cell Chemical Biology, 2022, 29, 1465-1466.	2.5	3
138	Advancing New Chemical Modalities into Clinical Studies. ACS Medicinal Chemistry Letters, 2022, 13, 1691-1698.	1.3	13
139	cIAP1-based degraders induce degradation via branched ubiquitin architectures. Nature Chemical Biology, 2023, 19, 311-322.	3.9	10
140	Targeting Chromatin-Remodeling Factors in Cancer Cells: Promising Molecules in Cancer Therapy. International Journal of Molecular Sciences, 2022, 23, 12815.	1.8	4

#	ARTICLE	IF	CITATIONS
141	The evolution and polymorphism of mono-amino acid repeats in androgen receptor and their regulatory role in health and disease. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
142	PROTAC-DB 2.0: an updated database of PROTACs. <i>Nucleic Acids Research</i> , 2023, 51, D1367-D1372.	6.5	46
143	Current strategies for improving limitations of proteolysis targeting chimeras. <i>Chinese Chemical Letters</i> , 2023, 34, 107927.	4.8	2
145	Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy. <i>Pharmacological Research</i> , 2022, 186, 106529.	3.1	13
147	SETD6 Regulates E2-Dependent Human Papillomavirus Transcription. <i>Journal of Virology</i> , 2022, 96, .	1.5	3
148	Manipulating autophagic degradation in human diseases: from mechanisms to interventions. , 2022, 1, 120-148.		4
149	SMAD4 Loss Induces c-MYC-Mediated NLE1 Upregulation to Support Protein Biosynthesis, Colorectal Cancer Growth, and Metastasis. <i>Cancer Research</i> , 2022, 82, 4604-4623.	0.4	5
150	Molecular targeted therapy for anticancer treatment. <i>Experimental and Molecular Medicine</i> , 2022, 54, 1670-1694.	3.2	57
151	Small molecule inhibitors targeting the cancers. <i>MedComm</i> , 2022, 3, .	3.1	25
152	The Emerging Roles of E3 Ligases and DUBs in Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2023, 60, 247-263.	1.9	4
153	The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 975-990.	2.7	23
154	Progression of Antiviral Agents Targeting Viral Polymerases. <i>Molecules</i> , 2022, 27, 7370.	1.7	6
155	PROTACTing the kinome with covalent warheads. <i>Drug Discovery Today</i> , 2023, 28, 103417.	3.2	3
156	Structural optimization of novel Ras modulator for treatment of Colorectal cancer by promoting β -catenin and Ras degradation. <i>Bioorganic Chemistry</i> , 2023, 130, 106234.	2.0	0
158	Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders. <i>Nature Chemical Biology</i> , 2023, 19, 323-333.	3.9	36
159	A synthetic KLHL20 ligand to validate CUL3 as a potent E3 ligase for targeted protein degradation. <i>Genes and Development</i> , 0, , .	2.7	0
160	PROTACs in gastrointestinal cancers. <i>Molecular Therapy - Oncolytics</i> , 2022, 27, 204-223.	2.0	10
161	A Versatile and Sustainable Multicomponent Platform for the Synthesis of Protein Degraders: Proof-of-Concept Application to BRD4-Degrading PROTACs. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 15282-15299.	2.9	16

#	ARTICLE	IF	CITATIONS
162	Ubiquitin proteasome system in immune regulation and therapeutics. <i>Current Opinion in Pharmacology</i> , 2022, 67, 102310.	1.7	9
163	Targeting small heat shock proteins to degrade aggregates as a potential strategy in neurodegenerative diseases. <i>Ageing Research Reviews</i> , 2022, 82, 101769.	5.0	1
164	PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery. <i>Drug Discovery Today</i> , 2023, 28, 103395.	3.2	18
165	Nitriles: an attractive approach to the development of covalent inhibitors. <i>RSC Medicinal Chemistry</i> , 2023, 14, 201-217.	1.7	11
171	Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2023, 91, 89-95.	1.1	5
172	Targeting a transcriptional scler-axis to treat cardiac fibrosis. <i>European Heart Journal</i> , 0, , .	1.0	2
173	Chemical degradation of BTK/TEC as a novel approach to inhibit platelet function. <i>Blood Advances</i> , 0, , .	2.5	1
174	The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease. <i>Expert Review of Proteomics</i> , 2022, 19, 235-246.	1.3	3
175	OncoLoop: A Network-Based Precision Cancer Medicine Framework. <i>Cancer Discovery</i> , 2023, 13, 386-409.	7.7	10
177	Modeling the Effect of Cooperativity in Ternary Complex Formation and Targeted Protein Degradation Mediated by Heterobifunctional Degraders. <i>ACS Bio & Med Chem Au</i> , 2023, 3, 74-86.	1.7	10
178	Targeting HER2-positive breast cancer: advances and future directions. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 101-126.	21.5	140
179	Targeting CSC-related transcription factors by E3 ubiquitin ligases for cancer therapy. <i>Seminars in Cancer Biology</i> , 2022, 87, 84-97.	4.3	13
181	Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2023, 79, 129083.	1.0	3
182	PCNA degradation exhibits superior pharmacological effects over stoichiometric inhibition. <i>Cell Chemical Biology</i> , 2022, 29, 1571-1573.	2.5	1
184	Quantitative measurement of PROTAC intracellular accumulation. <i>Methods in Enzymology</i> , 2023, , 189-214.	0.4	0
185	The importance of controls in targeted protein degradation: Determining mechanism. <i>Methods in Enzymology</i> , 2022, , .	0.4	0
186	Apt-clean: Aptamer-mediated cleavage of extracellular antigen for the inhibition of membrane protein functions. <i>Biomaterials Science</i> , 0, , .	2.6	1
187	Design, synthesis, and biological evaluation of BRD4 degraders. <i>Bioorganic and Medicinal Chemistry</i> , 2023, 78, 117134.	1.4	6

#	ARTICLE	IF	CITATIONS
188	Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma. <i>European Journal of Medicinal Chemistry</i> , 2023, 247, 115033.	2.6	3
189	Substrate-selective small-molecule modulators of enzymes: Mechanisms and opportunities. <i>Current Opinion in Chemical Biology</i> , 2023, 72, 102231.	2.8	1
190	Functions of the aryl hydrocarbon receptor (AHR) beyond the canonical AHR/ARNT signaling pathway. <i>Biochemical Pharmacology</i> , 2023, 208, 115371.	2.0	24
191	PROTACS: A technology with a gold rush-like atmosphere. <i>European Journal of Medicinal Chemistry</i> , 2023, 247, 115037.	2.6	9
192	Insights on the biological functions and diverse regulation of RNA-binding protein 39 and their implication in human diseases. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2023, 1866, 194902.	0.9	4
193	PROTAC: targeted drug strategy. Principles and limitations. <i>Russian Chemical Bulletin</i> , 2022, 71, 2310-2334.	0.4	8
194	A Perspective on Newly Emerging Proteolysis-Targeting Strategies in Antimicrobial Drug Discovery. <i>Antibiotics</i> , 2022, 11, 1717.	1.5	6
195	Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degradator for Glioblastoma. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 15642-15662.	2.9	10
196	Synthesis of novel glutarimide derivatives via the Ugi multicomponent reaction: affinity towards the E3 ubiquitin ligase substrate receptor Cereblon. <i>Mendeleev Communications</i> , 2022, 32, 747-749.	0.6	0
197	Current Challenges in Small Molecule Proximity-Inducing Compound Development for Targeted Protein Degradation Using the Ubiquitin Proteasomal System. <i>Molecules</i> , 2022, 27, 8119.	1.7	3
198	Development of therapeutic antibodies for the treatment of diseases. <i>Molecular Biomedicine</i> , 2022, 3, .	1.7	19
199	IL-6/STAT3 signaling in tumor cells restricts the expression of frameshift-derived neoantigens by SMG1 induction. <i>Molecular Cancer</i> , 2022, 21, .	7.9	9
200	Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets. <i>Journal of the American Chemical Society</i> , 2022, 144, 22622-22632.	6.6	28
201	PROTAC therapy as a new targeted therapy for lung cancer. <i>Molecular Therapy</i> , 2023, 31, 647-656.	3.7	13
203	Targeted Protein Degradation for Infectious Diseases: from Basic Biology to Drug Discovery. <i>ACS Bio & Med Chem Au</i> , 2023, 3, 32-45.	1.7	6
204	Discovery of Coumarin-Based MEK1/2 PROTAC Effective in Human Cancer Cells. <i>ACS Medicinal Chemistry Letters</i> , 2023, 14, 92-102.	1.3	6
205	Proteostasis in aging-associated ocular disease. <i>Molecular Aspects of Medicine</i> , 2022, 88, 101157.	2.7	10
206	Discovery of the First Lactate Dehydrogenase Proteolysis Targeting Chimera Degradator for the Treatment of Pancreatic Cancer. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 596-610.	2.9	3

#	ARTICLE	IF	CITATIONS
207	A Cell-Permeant Nanobody-Based Degradator That Induces Fetal Hemoglobin. ACS Central Science, 2022, 8, 1695-1703.	5.3	12
208	Hypoxia deactivates epigenetic feedbacks via enzyme-derived clicking proteolysis-targeting chimeras. Science Advances, 2022, 8, .	4.7	14
210	dSTORM-based single-cell protein quantitative analysis can effectively evaluate the degradation ability of PROTACs. ChemBioChem, 0, , .	1.3	1
211	Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future. Molecules, 2022, 27, 8828.	1.7	7
213	Design, Synthesis and In Vitro Investigation of Cabozantinib-Based PROTACs to Target c-Met Kinase. Pharmaceutics, 2022, 14, 2829.	2.0	6
214	IFITM proteins assist cellular uptake of diverse linked chemotypes. Science, 2022, 378, 1097-1104.	6.0	12
215	Health horizons: Future trends and technologies from the European Medicines Agency's horizon scanning collaborations. Frontiers in Medicine, 0, 9, .	1.2	7
216	Targeted Protein Degradation: Clinical Advances in the Field of Oncology. International Journal of Molecular Sciences, 2022, 23, 15440.	1.8	8
217	Targeted protein degradation by Trim-Away using cell resealing coupled with microscopic image-based quantitative analysis. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	0
218	10q26 "The enigma in age-related macular degeneration. Progress in Retinal and Eye Research, 2023, 96, 101154.	7.3	1
219	Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors. Journal of the American Chemical Society, 2023, 145, 385-391.	6.6	33
220	PIP kinases: A versatile family that demands further therapeutic attention. Advances in Biological Regulation, 2022, , 100939.	1.4	1
222	Checkpoint Nano-PROTACs for Activatable Cancer Photo-Immunotherapy. Advanced Materials, 2023, 35, .	11.1	24
223	Cellular functions and molecular mechanisms of ubiquitination in osteosarcoma. Frontiers in Oncology, 0, 12, .	1.3	1
224	Designing Selective Drug-like Molecular Glues for the Glucocorticoid Receptor/14-3-3 Protein-Protein Interaction. Journal of Medicinal Chemistry, 2022, 65, 16818-16828.	2.9	4
225	PROTAC Degradators of Androgen Receptor-Integrated Dissolving Microneedles for Androgenetic Alopecia and Recrudescence Treatment via Single Topical Administration. Small Methods, 2023, 7, .	4.6	9
226	Advancing targeted protein degradation for metabolic diseases therapy. Pharmacological Research, 2023, 188, 106627.	3.1	13
227	Structure-based design of selective, orally available salt-inducible kinase inhibitors that stimulate bone formation in mice. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	16

#	ARTICLE	IF	CITATIONS
228	Targeted protein degradation as an antiviral approach. <i>Antiviral Research</i> , 2023, 210, 105480.	1.9	4
229	Industry update for May 2022. <i>Therapeutic Delivery</i> , 0, , .	1.2	0
230	Battles against aberrant KEAP1-NRF2 signaling in lung cancer: intertwined metabolic and immune networks. <i>Theranostics</i> , 2023, 13, 704-723.	4.6	12
231	The roles of proteases in prostate cancer. <i>IUBMB Life</i> , 2023, 75, 493-513.	1.5	8
232	Basal cell adhesion molecule promotes metastasis-associated processes in ovarian cancer. <i>Clinical and Translational Medicine</i> , 2023, 13, .	1.7	1
233	Lethal activity of BRD4 PROTAC degrader QCA570 against bladder cancer cells. <i>Frontiers in Chemistry</i> , 0, 11, .	1.8	1
234	Evolution of nanobodies specific for BCL11A. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	6
235	Emerging TACnology: Heterobifunctional Small Molecule Inducers of Targeted Posttranslational Protein Modifications. <i>Molecules</i> , 2023, 28, 690.	1.7	5
236	E3 ligase ligand optimization of Clinical PROTACs. <i>Frontiers in Chemistry</i> , 0, 11, .	1.8	8
237	Advancements in lead therapeutic phytochemicals polycystic ovary syndrome: A review. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
238	PROTACs: Promising approach for anticancer therapy. <i>Cancer Letters</i> , 2023, 556, 216065.	3.2	5
239	Chemically engineering cells for precision medicine. <i>Chemical Society Reviews</i> , 2023, 52, 1068-1102.	18.7	22
240	Targeting protein clearance pathways in <i>GBA1</i> -associated Parkinson disease. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 1031-1035.	1.5	1
241	A Mechanistic Pharmacodynamic Modeling Framework for the Assessment and Optimization of Proteolysis Targeting Chimeras (PROTACs). <i>Pharmaceutics</i> , 2023, 15, 195.	2.0	6
242	Involvement of heterologous ubiquitination including linear ubiquitination in Alzheimer's disease and amyotrophic lateral sclerosis. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	1.6	2
243	E3-Specific Degradation Discovery by Dynamic Tracing of Substrate Receptor Abundance. <i>Journal of the American Chemical Society</i> , 2023, 145, 1176-1184.	6.6	11
244	DNA-modularized construction of bivalent ligands precisely regulates receptor binding and activation. <i>CheM</i> , 2023, 9, 901-923.	5.8	4
246	Life mimics art. <i>Cell Research</i> , 0, , .	5.7	0

#	ARTICLE	IF	CITATIONS
247	Conformational Sampling Deciphers the Chameleonic Properties of a VHL-Based Degradер. <i>Pharmaceutics</i> , 2023, 15, 272.	2.0	5
248	The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	14
249	Site-Specific Antibody Conjugation with Payloads beyond Cytotoxins. <i>Molecules</i> , 2023, 28, 917.	1.7	12
250	SLiM-binding pockets: an attractive target for broad-spectrum antivirals. <i>Trends in Biochemical Sciences</i> , 2023, 48, 420-427.	3.7	9
251	Payload diversification: a key step in the development of antibodyâ€“drug conjugates. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	6.9	42
252	Solubility Enhanced Formulation Approaches to Overcome Oral Delivery Obstacles of PROTACs. <i>Pharmaceutics</i> , 2023, 15, 156.	2.0	7
253	Discovery of the GSH responsive â€œY-PROTACsâ€“targeting ALK and CDK4/6 as a potential treatment for cancer. <i>European Journal of Medicinal Chemistry</i> , 2023, 248, 115082.	2.6	4
254	Degradерâ€“Antibody Conjugates: Emerging New Modality. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 140-148.	2.9	11
255	MS/MS-Based Molecular Networking: An Efficient Approach for Natural Products Dereplication. <i>Molecules</i> , 2023, 28, 157.	1.7	11
256	Therapeutic Strategies to Activate p53. <i>Pharmaceutics</i> , 2023, 16, 24.	1.7	10
257	CIDE-stepping E3s. <i>Nature Chemical Biology</i> , 2023, 19, 3-4.	3.9	0
258	Targeted Protein Degradation Induced by HEMTACs Based on HSP90. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 733-751.	2.9	7
259	Eliminating oncogenic RAS: back to the future at the drawing board. <i>Biochemical Society Transactions</i> , 2023, 51, 447-456.	1.6	9
260	Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy. <i>Pharmaceutics</i> , 2023, 15, 411.	2.0	7
261	Development of Nitroso-Based Probes for Labeling and Regulation of RAS Proteins in Cancer Cells via Sequential Ene-Ligation and Oxime Condensation. <i>Journal of Organic Chemistry</i> , 2023, 88, 1762-1771.	1.7	4
262	Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2645.	1.8	4
263	The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and disorder. <i>Biochemical Society Transactions</i> , 2023, 51, 125-135.	1.6	7
264	Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2289.	1.8	8

#	ARTICLE	IF	CITATIONS
265	Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach. ACS Chemical Biology, 2023, 18, 25-33.	1.6	9
266	Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity. Science Advances, 2023, 9, .	4.7	6
267	Peptide-based PROTACs: Current Challenges and Future Perspectives. Current Medicinal Chemistry, 2024, 31, 208-222.	1.2	2
268	Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations. Acta Pharmaceutica Sinica B, 2023, 13, 2715-2735.	5.7	4
269	Taming diamines and acyl chlorides by carbon dioxide in selective mono-acylation reactions. Green Chemistry, 2023, 25, 1332-1338.	4.6	2
270	EFMC: Trends in Medicinal Chemistry and Chemical Biology. ChemBioChem, 2023, 24, .	1.3	2
271	A two-faced selectivity solution to target SMARCA2 for cancer therapy. Nature Communications, 2023, 14, .	5.8	1
272	Synthesis and Biological Activity of a VHL-Based PROTAC Specific for p38 β . Cancers, 2023, 15, 611.	1.7	4
273	The evolving role of investigative toxicology in the pharmaceutical industry. Nature Reviews Drug Discovery, 2023, 22, 317-335.	21.5	29
274	The emerging role of proteolysis targeting chimeras (PROTACs) in the treatment of Alzheimer's disease. Medicinal Chemistry Research, 0, , .	1.1	0
275	Targeted Biomolecule Regulation Platform: A Split-and-Mix PROTAC Approach. Journal of the American Chemical Society, 2023, 145, 7879-7887.	6.6	11
276	Targeted therapy based on ubiquitin-specific proteases, signalling pathways and E3 ligases in non-small-cell lung cancer. Frontiers in Oncology, 0, 13, .	1.3	1
277	HiBiT-SpyTag: A Minimal Tag for Covalent Protein Capture and Degradation Development. ACS Chemical Biology, 2023, 18, 933-941.	1.6	5
278	Targeted protein degradation bypassing Cereblon and Von Hippel-Lindau. Innovation(China), 2023, , 100422.	5.2	0
280	On Ternary Complex Stability in Protein Degradation: In Silico Molecular Glue Binding Affinity Calculations. Journal of Chemical Information and Modeling, 2023, 63, 2382-2392.	2.5	4
281	PROTACs: Novel tools for improving immunotherapy in cancer. Cancer Letters, 2023, 560, 216128.	3.2	6
282	Significance of RB Loss in Unlocking Phenotypic Plasticity in Advanced Cancers. Molecular Cancer Research, 2023, 21, 497-510.	1.5	4
283	Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance. , 2023, 244, 108371.		5

#	ARTICLE	IF	CITATIONS
284	Targeted protein degradation in cancers: Orthodox PROTACs and beyond. <i>Innovation(China)</i> , 2023, 4, 100413.	5.2	4
285	Targeted protein posttranslational modifications by chemically induced proximity for cancer therapy. <i>Journal of Biological Chemistry</i> , 2023, 299, 104572.	1.6	9
286	A practical α -preTACs-cytoblot platform accelerates the streamlined development of PROTAC-based protein degraders. <i>European Journal of Medicinal Chemistry</i> , 2023, 251, 115248.	2.6	2
287	Interaction modules that impart specificity to disordered protein. <i>Trends in Biochemical Sciences</i> , 2023, 48, 477-490.	3.7	22
288	Antiviral PROTACs: Opportunity borne with challenge. , 2023, 2, 100092.		12
289	From PROTAC to inhibitor: Structure-guided discovery of potent and orally bioavailable BET inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2023, 251, 115246.	2.6	1
290	Discovery of novel protein degraders based on bioorthogonal reaction-driven intracellular self-assembly strategy. <i>Bioorganic Chemistry</i> , 2023, 135, 106497.	2.0	3
291	The N-degron pathway: From basic science to therapeutic applications. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2023, 1866, 194934.	0.9	4
292	c-Myc-Targeting PROTAC Based on a TNA-DNA Bivalent Binder for Combination Therapy of Triple-Negative Breast Cancer. <i>Journal of the American Chemical Society</i> , 2023, 145, 9334-9342.	6.6	22
293	2-Aminobenzothiazoles in anticancer drug design and discovery. <i>Bioorganic Chemistry</i> , 2023, 135, 106477.	2.0	9
294	Ugi reaction-assisted assembly of covalent PROTACs against glutathione peroxidase 4. <i>Bioorganic Chemistry</i> , 2023, 134, 106461.	2.0	3
295	CRISPR Screen Reveals BRD2/4 Molecular Glue-like Degradation via Recruitment of DCAF16. <i>ACS Chemical Biology</i> , 2023, 18, 331-339.	1.6	19
296	A Physiologically Responsive Nanocomposite Hydrogel for Treatment of Head and Neck Squamous Cell Carcinoma via Proteolysis-Targeting Chimeras Enhanced Immunotherapy. <i>Advanced Materials</i> , 2023, 35, .	11.1	11
297	Crizotinib-based proteolysis targeting chimera suppresses gastric cancer by promoting $\langle \text{MET} \rangle$ degradation. <i>Cancer Science</i> , 2023, 114, 1958-1971.	1.7	4
298	Characterizing the binding of glycoprotein VI with nanobody 35 reveals a novel monomeric structure of glycoprotein VI where the conformation of D1+D2 is independent of dimerization. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 317-328.	1.9	2
299	PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities. <i>Molecules</i> , 2023, 28, 1217.	1.7	5
300	Aptamer- α -LYTACs for Targeted Degradation of Extracellular and Membrane Proteins. <i>Angewandte Chemie</i> , 2023, 135, .	1.6	1
301	Predictive Modeling of PROTAC Cell Permeability with Machine Learning. <i>ACS Omega</i> , 2023, 8, 5901-5916.	1.6	8

#	ARTICLE	IF	CITATIONS
302	Aptamer- γ LYTACs for Targeted Degradation of Extracellular and Membrane Proteins. <i>Angewandte Chemie - International Edition</i> , 2023, 62, .	7.2	15
303	Development of Human Carbonic Anhydrase II Heterobifunctional Degraders. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 2789-2803.	2.9	7
304	Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2023, 13, 1210-1229.	7.7	18
305	Sequence and structure alignments in post-AlphaFold era. <i>Current Opinion in Structural Biology</i> , 2023, 79, 102539.	2.6	2
306	Synthesis of novel glutarimide derivatives via the Michael addition of (hetero)aromatic thiols: pronounced effect of sulfur oxidation on cytotoxicity towards multiple myeloma cell lines. <i>Mendeleev Communications</i> , 2023, 33, 67-69.	0.6	0
307	The role and regulation of Maf proteins in cancer. <i>Biomarker Research</i> , 2023, 11, .	2.8	5
308	Development of Substituted Phenyl Dihydrouracil as the Novel Achiral Cereblon Ligands for Targeted Protein Degradation. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 2904-2917.	2.9	13
309	Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader. <i>Oncogene</i> , 2023, 42, 994-1009.	2.6	6
310	Ubiquitin-modifying enzymes in Huntington's disease. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	1.6	5
311	Proteome-Wide Fragment-Based Ligand and Target Discovery. <i>Israel Journal of Chemistry</i> , 2023, 63, .	1.0	1
312	Trends in Molecular Properties, Bioavailability, and Permeability across the Bayer Compound Collection. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 2347-2360.	2.9	22
314	BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2023, 29, 1807-1821.	3.2	6
315	Protein degraders enter the clinic – a new approach to cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 265-278.	12.5	100
316	Synthetic E2-Ub-nucleosome conjugates for studying nucleosome ubiquitination. <i>CheM</i> , 2023, 9, 1221-1240.	5.8	17
317	The Role of CREBBP/EP300 and Its Therapeutic Implications in Hematological Malignancies. <i>Cancers</i> , 2023, 15, 1219.	1.7	11
318	Development of a bispecific DNA-aptamer-based lysosome-targeting chimera for HER2 protein degradation. <i>Cell Reports Physical Science</i> , 2023, 4, 101296.	2.8	5
321	Recent advances in targeted protein degraders as potential therapeutic agents. <i>Molecular Diversity</i> , 2024, 28, 309-333.	2.1	4
323	SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities. <i>Molecular Cancer</i> , 2023, 22, .	7.9	12

#	ARTICLE	IF	CITATIONS
324	Metastasiertes nichtkleinzelliges Lungenkarzinom: Zielgerichtete Therapie " was uns in der Zukunft erwartet. , 0, , .		0
325	Delivering on the promise of protein degraders. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 410-427.	21.5	16
326	PROTAC antibiotics: the time is now. <i>Expert Opinion on Drug Discovery</i> , 2023, 18, 363-370.	2.5	2
327	E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 3173-3194.	2.9	13
329	Computer aided drug design in the development of proteolysis targeting chimeras. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 2058-2067.	1.9	3
330	Current Status of Oligonucleotide-Based Protein Degraders. <i>Pharmaceutics</i> , 2023, 15, 765.	2.0	2
331	Role of bromodomain and extraterminal (BET) proteins in prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2023, 32, 213-228.	1.9	3
332	Addressing Transcriptional Dysregulation in Cancer through CDK9 Inhibition. <i>Biochemistry</i> , 2023, 62, 1114-1123.	1.2	6
333	Cereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges?. <i>Pharmaceutics</i> , 2023, 15, 812.	2.0	7
334	A covalent BTK ternary complex compatible with targeted protein degradation. <i>Nature Communications</i> , 2023, 14, .	5.8	4
335	Regulation of MAPK Signaling Pathways by the Large HERC Ubiquitin Ligases. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4906.	1.8	2
336	Up-regulated Circular RNAs in Colorectal Cancer: New Entities for Therapy and Tools for Identification of Therapeutic Targets. <i>Cancer Genomics and Proteomics</i> , 2023, 20, 132-153.	1.0	0
337	Recent advances in the development of RIPK2 modulators for the treatment of inflammatory diseases. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	7
338	Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2023, 15, 1635.	1.7	10
339	Advantages of X-ray Crystallography in Drug Discovery Research. <i>Nihon Kessho Gakkaishi</i> , 2023, 65, 51-54.	0.0	0
340	A novel selective estrogen receptor degrader induces cell cycle arrest in breast cancer via ER α degradation and the autophagy-lysosome pathway. <i>Bioorganic and Medicinal Chemistry</i> , 2023, 82, 117235.	1.4	1
341	Anticancer Small-Molecule Agents Targeting Eukaryotic Elongation Factor 1A: State of the Art. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5184.	1.8	4
342	Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5190.	1.8	2

#	ARTICLE	IF	CITATIONS
343	ARE-PROTACs Enable Co-degradation of an Nrf2-MafG Heterodimer. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 6070-6081.	2.9	5
344	Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 4197-4214.	2.9	9
345	TIP60 is required for tumorigenesis in non-small cell lung cancer. <i>Cancer Science</i> , 2023, 114, 2400-2413.	1.7	3
346	Use of FCCS in drug discovery and development and presentation of a novel dedicated instrument for industrial FCCS applications. , 2023, , .		0
347	A massive machine regulates cell death. <i>Science</i> , 2023, 379, 1093-1094.	6.0	2
348	Intracellular Antibodies for Drug Discovery and as Drugs of the Future. <i>Antibodies</i> , 2023, 12, 24.	1.2	2
349	Drug discovery processes: When and where the rubber meets the road. , 2023, , 339-415.		1
350	Deep Annotation of Donated Chemical Probes (DCP) in Organotypic Human Liver Cultures and Patient-Derived Organoids from Tumor and Normal Colorectum. <i>ACS Chemical Biology</i> , 2023, 18, 822-836.	1.6	0
351	Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2023, 12, 615-628.	1.3	6
352	PROTAC-Mediated Selective Degradation of Cytosolic Soluble Epoxide Hydrolase Enhances ER Stress Reduction. <i>ACS Chemical Biology</i> , 2023, 18, 884-896.	1.6	1
353	Intracellular antibodies and biodegraders: Beyond small molecules and back again. <i>Current Opinion in Biomedical Engineering</i> , 2023, 27, 100455.	1.8	0
354	Discovery of Potent and Highly Selective Interleukin-2-Inducible T-Cell Kinase Degradors with In Vivo Activity. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 4979-4998.	2.9	0
355	Receptor-interacting protein kinase 1 (RIPK1) inhibitor: a review of the patent literature (2018-present). <i>Expert Opinion on Therapeutic Patents</i> , 2023, 33, 101-124.	2.4	3
356	The application of targeted protein degradation technologies to G protein-coupled receptors. <i>British Journal of Pharmacology</i> , 0, , .	2.7	2
357	Ligation to Scavenging Strategy Enables On-Demand Termination of Targeted Protein Degradation. <i>Journal of the American Chemical Society</i> , 2023, 145, 7218-7229.	6.6	8
358	Discovery of a Potent and Selective Targeted NSD2 Degradator for the Reduction of H3K36me2. <i>Journal of the American Chemical Society</i> , 2023, 145, 8176-8188.	6.6	9
359	Development of Son of Sevenless Homologue 1 (SOS1) Modulators To Treat Cancers by Regulating RAS Signaling. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 4324-4341.	2.9	9
360	PROTAC™ing oncoproteins: targeted protein degradation for cancer therapy. <i>Molecular Cancer</i> , 2023, 22, .	7.9	18

#	ARTICLE	IF	CITATIONS
361	Heterobifunctional Ligase Recruiters Enable pan-Degradation of Inhibitor of Apoptosis Proteins. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 4703-4733.	2.9	2
362	Cu-catalysed three-component C-H trifluoroalkylation of glycine derivatives: access to diverse CF ₃ -containing amino acids. <i>Organic Chemistry Frontiers</i> , 2023, 10, 2301-2309.	2.3	4
363	Receptor Elimination by E3 Ubiquitin Ligase Recruitment (REULR): A Targeted Protein Degradation Toolbox. <i>ACS Synthetic Biology</i> , 2023, 12, 1081-1093.	1.9	9
364	Developing an Affinity-Based Chemical Proteomics Method to <i>In Situ</i> Capture Amorphous Aggregated Proteome and Profile Its Heterogeneity in Stressed Cells. <i>Analytical Chemistry</i> , 2023, 95, 6358-6366.	3.2	6
365	Biophysical and Computational Approaches to Study Ternary Complexes: A Cooperative Relationship to Rationalize Targeted Protein Degradation. <i>ChemBioChem</i> , 2023, 24, .	1.3	8
366	ERK1/2 inhibitors act as monovalent degraders inducing ubiquitylation and proteasome-dependent turnover of ERK2, but not ERK1. <i>Biochemical Journal</i> , 0, , .	1.7	2
367	Rational Design in Photopharmacology with Molecular Photoswitches. <i>Angewandte Chemie</i> , 2023, 135, .	1.6	3
368	Discovery of ML210-Based glutathione peroxidase 4 (GPX4) degrader inducing ferroptosis of human cancer cells. <i>European Journal of Medicinal Chemistry</i> , 2023, 254, 115343.	2.6	5
369	Rational Design in Photopharmacology with Molecular Photoswitches. <i>Angewandte Chemie - International Edition</i> , 2023, 62, .	7.2	25
370	Deciphering the Clinical Significance and Kinase Functions of GSK3 β in Colon Cancer by Proteomics and Phosphoproteomics. <i>Molecular and Cellular Proteomics</i> , 2023, 22, 100545.	2.5	4
372	Super-enhancer-driven TOX2 mediates oncogenesis in Natural Killer/T Cell Lymphoma. <i>Molecular Cancer</i> , 2023, 22, .	7.9	3
373	A New Wave of Targeting "Undruggable" Wnt Signaling for Cancer Therapy: Challenges and Opportunities. <i>Cells</i> , 2023, 12, 1110.	1.8	8
374	A small-molecule degrader of TET3 as treatment for anorexia nervosa in an animal model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	3
375	Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein Degraders. <i>Drug Metabolism and Disposition</i> , 2023, 51, 792-803.	1.7	8
376	Driving the degradation of oncofusion proteins for targeted cancer therapy. <i>Drug Discovery Today</i> , 2023, 28, 103584.	3.2	1
377	Targeted protein degrader development for cancer: advances, challenges, and opportunities. <i>Trends in Pharmacological Sciences</i> , 2023, 44, 303-317.	4.0	9
378	Bifunctional robots inducing targeted protein degradation. <i>European Journal of Medicinal Chemistry</i> , 2023, 255, 115384.	2.6	2
379	Open resources for chemical probes and their implications for future drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2023, 18, 505-513.	2.5	0

#	ARTICLE	IF	CITATIONS
380	Glutathioneâ€Scavenging Nanoparticleâ€Mediated PROTACs Delivery for Targeted Protein Degradation and Amplified Antitumor Effects. <i>Advanced Science</i> , 2023, 10, .	5.6	10
381	Selected Approaches to Disrupting Proteinâ€Protein Interactions within the MAPK/RAS Pathway. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7373.	1.8	2
382	The Tale of DJ-1 (PARK7): A Swiss Army Knife in Biomedical and Psychological Research. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7409.	1.8	2
383	Discovery of highly potent HDAC8 PROTACs with anti-tumor activity. <i>Bioorganic Chemistry</i> , 2023, 136, 106546.	2.0	5
384	Targeting of SOS1: from SOS1 Activators to Proteolysis Targeting Chimeras. <i>Current Pharmaceutical Design</i> , 2023, 29, 1741-1746.	0.9	4
385	SAA1 Has Potential as a Prognostic Biomarker Correlated with Cell Proliferation, Migration, and an Indicator for Immune Infiltration of Tumor Microenvironment in Clear Cell Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7505.	1.8	0
386	Discovery of a miniaturized PROTAC with potent activity and high selectivity. <i>Bioorganic Chemistry</i> , 2023, 136, 106556.	2.0	3
387	Structure-activity relationship study of RSL3-based GPX4 degraders and its potential noncovalent optimization. <i>European Journal of Medicinal Chemistry</i> , 2023, 255, 115393.	2.6	6
388	TRAP1 S-nitrosylation as a model of population-shift mechanism to study the effects of nitric oxide on redox-sensitive oncoproteins. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	1
389	Targeted protein degradation might present a novel therapeutic approach in the fight against African trypanosomiasis. <i>European Journal of Pharmaceutical Sciences</i> , 2023, 186, 106451.	1.9	3
406	Protein degradation-based cancer therapy. , 2023, , 637-679.		0
441	Chemically induced degradation of epigenetic targets. <i>Chemical Society Reviews</i> , 2023, 52, 4313-4342.	18.7	2
455	Rethinking our approach to cancer metabolism to deliver patient benefit. <i>British Journal of Cancer</i> , 0, , .	2.9	0
458	Editorial: Brain metabolic imaging by magnetic resonance imaging and spectroscopy: methods and clinical applications. <i>Frontiers in Neuroscience</i> , 0, 17, .	1.4	0
461	Targeting Ribonucleases with Small Molecules and Bifunctional Molecules. <i>ACS Chemical Biology</i> , 0, , .	1.6	0
468	Formation of C(sp ²)â€C(sp ³) Bonds Instead of Amide Câ€N Bonds from Carboxylic Acid and Amine Substrate Pools by Decarbonylative Cross-Electrophile Coupling. <i>Journal of the American Chemical Society</i> , 2023, 145, 9951-9958.	6.6	12
475	PROTAC-Induced Glycogen Synthase Kinase 3 β Degradation as a Potential Therapeutic Strategy for Alzheimerâ€™s Disease. <i>ACS Chemical Neuroscience</i> , 2023, 14, 1963-1970.	1.7	4
482	Targeting MDM2 for the development of a new cancer therapy: progress and challenges. <i>Medicinal Chemistry Research</i> , 2023, 32, 1334-1344.	1.1	1

#	ARTICLE	IF	CITATIONS
488	Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 8339-8381.	2.9	13
489	Carrier-Free Nano-PROTACs to Amplify Photodynamic Therapy Induced DNA Damage through BRD4 Degradation. <i>Nano Letters</i> , 2023, 23, 6193-6201.	4.5	3
493	Opportunities and challenges of protein-based targeted protein degradation. <i>Chemical Science</i> , 2023, 14, 8433-8447.	3.7	3
523	Methods for computer-assisted PROTAC design. <i>Methods in Enzymology</i> , 2023, , 311-340.	0.4	1
530	PROTAC chemical probes for histone deacetylase enzymes. <i>RSC Chemical Biology</i> , 2023, 4, 623-634.	2.0	1
534	Therapeutic resistance to anti-oestrogen therapy in breast cancer. <i>Nature Reviews Cancer</i> , 2023, 23, 673-685.	12.8	10
536	HYDROGEN/DEUTERIUM EXCHANGE-MASS SPECTROMETRY IN MEDICINAL CHEMISTRY. <i>Medicinal Chemistry Reviews</i> , 0, , 465-487.	0.1	0
566	Hunting down the shapeshifters. <i>Nature Chemical Biology</i> , 0, , .	3.9	0
574	Proximity-inducing modalities: the past, present, and future. <i>Chemical Society Reviews</i> , 2023, 52, 5485-5515.	18.7	5
579	Research Progress in Function and Regulation of E3 Ubiquitin Ligase SMURF1. <i>Current Medical Science</i> , 2023, 43, 855-868.	0.7	0
581	First-in-class metallo-PROTAC as an effective degrader of select Pt-binding proteins. <i>Chemical Communications</i> , 2023, 59, 12641-12644.	2.2	1
598	The roles of ubiquitination in AML. <i>Annals of Hematology</i> , 0, , .	0.8	0
609	Ubiquitination Process Mediates Prostate Cancer Development and Metastasis through Multiple Mechanisms. <i>Cell Biochemistry and Biophysics</i> , 2024, 82, 77-90.	0.9	0
613	MYC in liver cancer: mechanisms and targeted therapy opportunities. <i>Oncogene</i> , 2023, 42, 3303-3318.	2.6	1
644	A mucin degrader for cancer therapy. <i>Nature Biotechnology</i> , 0, , .	9.4	0
673	Discovery of small molecule degraders for modulating cell cycle. <i>Frontiers of Medicine</i> , 2023, 17, 823-854.	1.5	0
686	Biophysical screening and characterisation in medicinal chemistry. <i>Progress in Medicinal Chemistry</i> , 2023, , 61-104.	4.1	1
691	SMALL-MOLECULE RNA-SPLICING MODULATORS. <i>Medicinal Chemistry Reviews</i> , 0, , 399-417.	0.1	0

#	ARTICLE	IF	CITATIONS
703	Unconventional roles of chromatin remodelers and long non-coding RNAs in cell division. Cellular and Molecular Life Sciences, 2023, 80, .	2.4	0
707	New Therapeutic Modalities: Transforming Drug Discovery and Development. , 2023, , 1-21.		1
733	Utilising the intrinsic fluorescence of pomalidomide for imaging applications. Chemical Communications, 2023, 59, 14532-14535.	2.2	1
742	FBDD & De Novo Drug Design. , 2023, , 159-201.		0
760	Recent Advances of RNA m6A Modifications in Cancer Immunoediting and Immunotherapy. Cancer Treatment and Research, 2023, , 49-94.	0.2	0
782	Exploring the next generation of antibody–drug conjugates. Nature Reviews Clinical Oncology, 2024, 21, 203-223.	12.5	5
814	Nano-PROTACs: state of the art and perspectives. Nanoscale, 2024, 16, 4378-4391.	2.8	1
860	Chemical rewiring of ubiquitination by degraders and their selectivity routes. Nature Structural and Molecular Biology, 2024, 31, 205-207.	3.6	0